James P. Long, PhD
Department of Biostatistics, Division of Discovery Science
About James P. Long
Visit Dr. Long's personal website for more information on his research and teaching.
Read More
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Biostatistics, Division of Discovery Science, University of Texas MD Anderson Cancer Center, Houston, TX
Adjunct Associate Professor, Department of Statistics, Rice University, Houston, TX
Associate Professor, Department of Quantitative Sciences, Graduate School of Biological Sciences, Houston, TX
Education & Training
Degree-Granting Education
| 2013 | University of California, Berkeley, Berkeley, California, US, Statistics, Ph.D |
| 2008 | Columbia University, New York, New York, US, Mathematics and Statistics, BA |
Experience & Service
Academic Appointments
Adjunct Assistant Professor, Department of Statistics, Texas A&M University, College Station, TX, 2018 - 2020
Assistant Professor, Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024
Research Fellow, Statistical and Applied Mathematical Sciences Institute, Research Triangle Park, NC, 2016 - 2016
Assistant Professor, Department of Statistics, Texas A&M University, College Station, TX, 2013 - 2018
Institutional Committee Activities
Associate Member, IRB5, 2019 - Present
Associate Member, DSMB, 2019 - 2022
Senator, Faculty Senate, 2015 - 2018
Honors & Awards
| Citadel Fellowship, Citadel LLC | |
| Korean International Statistics Society Career Development Award, Korean International Statistics Society |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Muthusivarajan R, Celaya A, Yung JP, Long JP, Viswanath SE, Marcus DS, Chung C, Fuentes D. Evaluating the relationship between magnetic resonance image quality metrics and deep learning-based segmentation accuracy of brain tumors. Med Phys 51(7):4898-4906, 2024. e-Pub 2024. PMID: 38640464.
- Campbell MT, Balderrama-Brondani V, Jimenez C, Tamsen G, Marcal LP, Varghese J, Shah AY, Long JP, Zhang M, Ochieng J, Haymaker C, Habra MA. Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial. Lancet Oncol 25(5):649-657, 2024. e-Pub 2024. PMID: 38608694.
- Jimenez C, Habra MA, Campbell MT, Tamsen G, Cruz-Goldberg D, Long JP, Bassett R, Dantzer R, Balderrama-Brondani V, Varghese J, Lu Y. Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial. Lancet Oncol 25(5):658-667, 2024. e-Pub 2024. PMID: 38608693.
- Arthur J, Edwards T, Lu Z, Amoateng MD, Koom-Dadzie K, Zhu H, Long JP, Do KA, Bruera E. Healthcare provider perceptions and reported practices regarding opioid prescription for patients with chronic cancer pain. Support Care Cancer 32(2):121, 2024. e-Pub 2024. PMID: 38252311.
- Zhang X, Irajizad E, Hoffman KL, Fahrmann JF, Li F, Seo YD, Browman GJ, Dennison JB, Vykoukal J, Luna PN, Siu W, Wu R, Murage E, Ajami NJ, McQuade JL, Wargo JA, Long JP, Do KA, Lampe JW, Basen-Engquist KM, Okhuysen PC, Kopetz S, Hanash SM, Petrosino JF, Scheet P, Daniel CR. Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. EBioMedicine 98, 2023. PMID: 38040541.
- Buszek SM, Tran B, Long JP, Luo D, Suki D, Li J, Ferguson S, Chung C. Postoperative Management of Recurrence After Radiosurgery and Surgical Resection for Brain Metastases and Predicting Benefit From Adjuvant Radiation. Pract Radiat Oncol 13(6):e499-e503, 2023. PMID: 37295724.
- Long JP, Zhu H, Do KA, Ha MJ. Estimating Causal Effects with Hidden Confounding using Instrumental Variables and Environments. Electronic Journal of Statistics 17(2):None, 2023. PMID: 38957485.
- Irajizad E, Fahrmann JF, Marsh T, Vykoukal J, Dennison JB, Long JP, Do KA, Feng Z, Hanash S, Ostrin EJ. Mortality Benefit of a Blood-Based Biomarker Panel for Lung Cancer on the Basis of the Prostate, Lung, Colorectal, and Ovarian Cohort. J Clin Oncol 41(27):4360-4368, 2023. PMID: 37379494.
- Irajizad E, Kenney A, Tang T, Vykoukal J, Wu R, Murage E, Dennison JB, Sans M, Long JP, Loftus M, Chabot JA, Kluger MD, Kastrinos F, Brais L, Babic A, Jajoo K, Lee LS, Clancy TE, Ng K, Bullock A, Genkinger JM, Maitra A, Do KA, Yu B, Wolpin BM, Hanash S, Fahrmann JF. A blood-based metabolomic signature predictive of risk for pancreatic cancer. Cell Rep Med 4(9):101194, 2023. PMID: 37729870.
- Long JP, Shen Y. Detection method has independent prognostic significance in the PLCO lung screening trial. Sci Rep 13(1):13382, 2023. e-Pub 2023. PMID: 37591907.
- Huang L, Long JP, Irajizad E, Doecke JD, Do KA, Ha MJ. A unified mediation analysis framework for integrative cancer proteogenomics with clinical outcomes. Bioinformatics 39(1), 2023. PMID: 36648331.
- Singh S, Long JP, Tchakarov A, Dong Y, Yee C, Lin JS. Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis. JCI Insight None(None):None, 2022. e-Pub 2022. PMID: 36472921.
- Lopez BP, Mahvash A, Long JP, MGEH L, Kappadath SC. Factors modulating 99m Tc-MAA planar lung dosimetry for 90 Y radioembolization. J Appl Clin Med Phys 23(12), 2022. PMID: 35906892.
- Irajizad E, Han CY, Celestino J, Wu R, Murage E, Spencer R, Dennison JB, Vykoukal J, Long JP, Do KA, Drescher C, Lu K, Lu Z, Bast RC, Hanash S, Fahrmann JF. A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses. Clinical Cancer Research 28(21):4669-4676, 2022. PMID: 36037307.
- Gates EDH, Suki D, Celaya A, Weinberg JS, Prabhu SS, Sawaya R, Huse JT, Long JP, Fuentes D, Schellingerhout D. Cellular Density in Adult Glioma, Estimated with MR Imaging Data and a Machine Learning Algorithm, Has Prognostic Power Approaching World Health Organization Histologic Grading in a Cohort of 1181 Patients. AJNR Am J Neuroradiol 43(10):1411-1417, 2022. PMID: 36109124.
- Singh S, Clemente LC, Parra ER, Tchakarov A, Yang C, Li Y, Long JP, Yee C, Lin JS. Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates. Oncoimmunology 11(1), 2022. PMID: 36185804.
- Irajizad E, Fahrmann JF, Long JP, Vykoukal J, Kobayashi M, Capello M, Yu CY, Cai Y, Hsiao FC, Patel N, Park S, Peng Q, Dennison JB, Kato T, Tai MC, Taguchi A, Kadara H, Wistuba II, Katayama H, Do KA, Hanash SM, Ostrin EJ. A Comprehensive Search of Non-Canonical Proteins in Non-Small Cell Lung Cancer and Their Impact on the Immune Response. Int J Mol Sci 23(16), 2022. e-Pub 2022. PMID: 36012199.
- Soundararajan R, Viscuse P, Pilie P, Liu J, Logotheti S, Laberiano Fernández C, Lorenzini D, Hoang A, Lu W, Soto LMS, Wistuba II, Xu M, Song X, Shepherd PDA, Navone NM, Tidwell RSS, Lozano G, Logothetis C, Zhang J, Long JP, Estecio MR, Tzelepi V, Aparicio AM. Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components. Cancers (Basel) 14(13), 2022. e-Pub 2022. PMID: 35805010.
- Groot J, Ott M, Wei J, Kassab C, Fang D, Najem H, O'Brien B, Weathers SP, Matsouka CK, Majd NK, Harrison RA, Fuller GN, Huse JT, Long JP, Sawaya R, Rao G, MacDonald TJ, Priebe W, DeCuypere M, Heimberger AB. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncology 11(2), 2022. e-Pub 2022. PMID: 35575067.
- Najem H, Ott M, Kassab C, Rao A, Rao G, Marisetty A, Sonabend AM, Horbinski C, Verhaak R, Shankar A, Krishnan SN, Varn FS, Arrieta VA, Gupta P, Ferguson SD, Huse JT, Fuller GN, Long JP, Winkowski DE, Freiberg BA, James CD, Platanias LC, Lesniak MS, Burks JK, Heimberger AB. Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression. JCI Insight 7(9), 2022. e-Pub 2022. PMID: 35316217.
- Gupta AC, Owens CA, Shrestha S, Lee C, Smith SA, Weathers RE, Netherton T, Balter PA, Kry SF, Followill DS, Griffin KT, Long JP, Armstrong GT, Howell RM. Body Region-Specific 3D Age-Scaling Functions for Scaling Whole-Body Computed Tomography Anatomy for Pediatric Late Effects Studies. Biomed Phys Eng Express 8(2), 2022. PMID: 34874300.
- Long JP, Ha MJ. Sample selection bias in evaluation of prediction performance of causal models. Statistical Analysis and Data Mining 15(1):5-14, 2022. e-Pub 2021. PMID: 35498876.
- Wei J, Song R, Sabbagh A, Marisetty A, Shukla N, Fang D, Najem H, Ott M, Long JP, Zhai L, Lesniak MS, James CD, Platanias L, Curran M, Heimberger AB. Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system. Oncoimmunology 11(1), 2022. PMID: 35433114.
- Semba T, Wang X, Xie X, Cohen EN, Reuben JM, Dalby KN, Long JP, Hanh Phi LT, Tripathy D, Ueno NT. Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated with an Immunosuppressive Tumor Microenvironment. J Natl Cancer Inst 114(1):97-108, 2022. e-Pub 2021. PMID: 34250544.
- Irajizad E, Wu R, Vykoukal J, Murage E, Spencer R, Dennison JB, Moulder S, Ravenberg E, Lim B, Litton J, Tripathym D, Valero V, Damodaran S, Rauch GM, Adrada B, Candelaria R, White JB, Brewster A, Arun B, Long JP, Do KA, Hanash S, Fahrmann JF. Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Frontiers in Artificial Intelligence 5:876100, 2022. e-Pub 2022. PMID: 36034598.
- Teyateeti A, Mahvash A, Long JP, Abdelsalam M, Avritscher R, Kaseb A, Odisio B, Ravizzini G, Surasi D, Teyateeti A, Macapinlac H, Kappadath SC. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World J Gastroenterol 27(47):8166-8181, 2021. PMID: 35068861.
- Najem H, Marisetty A, Horbinski C, Long JP, Huse JT, Glitza Oliva IC, Ferguson SD, Kumthekar PU, Wainwright DA, Chen P, Lesniak MS, Burks JK, Heimberger AB. CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease. Front Immunol 12:745893, 2021. PMID: 34691054.
- Katayama H, Kobayashi M, Irajizad E, Sevillarno A, Patel N, Mao X, Rusling L, Vykoukal J, Cai Y, Hsiao F, Yu CY, Long JP, Liu J, Esteva F, Fahrmann J, Hanash S. Protein citrullination as a source of cancer neoantigens. J Immunother Cancer 9(6), 2021. PMID: 34112737.
- Chainitikun S, Espinosa Fernandez JR, Long JP, Iwase T, Kida K, Wang X, Saleem S, Lim B, Valero V, Ueno NT. Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. PLoS One 16(4):e0250057, 2021. PMID: 33861773.
- Fahrmann JF, Schmidt CM, Mao X, Irajizad E, Loftus M, Zhang J, Patel N, Vykoukal J, Dennison JB, Long JP, Do KA, Zhang J, Chabot JA, Kluger MD, Kastrinos F, Brais L, Babic A, Jajoo K, Lee LS, Clancy TE, Ng K, Bullock A, Genkinger J, Yip-Schneider MT, Maitra A, Wolpin BM, Hanash S. Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection. Gastroenterology 160(4):1373-1383.e6, 2021. PMID: 33333055.
- Fahrmann JF, Irajizad E, Kobayashi M, Vykoukal J, Dennison JB, Murage E, Wu R, Long JP, Do KA, Celestino J, Lu KH, Lu Z, Bast RC, Hanash S. A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer. Cancers (Basel) 13(4):1-22, 2021. e-Pub 2021. PMID: 33671595.
- Ferguson SD, Hodges TR, Majd NK, Alfaro-Munoz K, Al-Holou WN, Suki D, de Groot JF, Fuller GN, Xue L, Li M, Jacobs C, Rao G, Colen RR, Xiu J, Verhaak R, Spetzler D, Khasraw M, Sawaya R, Long JP, Heimberger AB. A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram. Neuro-Oncology Advances 3(1), 2021. PMID: 33426529.
- Capello M, Fahrmann JF, Rios Perez MV, Vykoukal JV, Irajizad E, Tripathi SC, Roife D, Bantis LE, Kang Y, Kundnani DL, Xu H, Prakash LR, Long JP, Katayama H, Fleury A, Ferri-Borgogno S, Baluya DL, Dennison JB, Aguilar-Bonavides C, Casabar JP, Celiktas M, Do KA, Fiehn O, Maitra A, Wang H, Feng Z, Chiao PJ, Katz MH, Fleming JB, Hanash SM. CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. JCO Precis Oncol 4:426-436, 2020. PMID: 35050739.
- Ott M, Tomaszowski KH, Marisetty A, Kong LY, Wei J, Duna M, Blumberg K, Ji X, Jacobs C, Fuller GN, Langford LA, Huse JT, Long JP, Hu J, Li S, Weinberg JS, Prabhu SS, Sawaya R, Ferguson S, Rao G, Lang FF, Curran MA, Heimberger AB. Glioma patient profiling reveals the dominant immune suppressive adenosine axis is refractory to immune function restoration. JCI Insight 5(17), 2020. e-Pub 2020. PMID: 32721947.
- Rao G, Latha K, Ott M, Sabbagh A, Marisetty A, Ling X, Zamler D, Doucette TA, Yang Y, Kong LY, Wei J, Fuller GN, Benavides F, Sonabend AM, Long JP, Li S, Curran M, Heimberger AB. Anti-PD-1 induces M1 polarization in the glioma microenvironment and exerts therapeutic efficacy in the absence of CD8 cytotoxic T cells. Clin Cancer Res 26(17):4699-4712, 2020. e-Pub 2020. PMID: 32554515.
- Chainitikun S, Long JP, Rodriguez-Bautista R, Iwase T, Tripathy D, Fujii T, Ueno NT. The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. Breast Cancer Res Treat None(None):None, 2020. e-Pub 2020. PMID: 32720114.
- Ott M, Kassab C, Marisetty A, Hashimoto Y, Wei J, Zamler DB, Leu JS, Tomaszowski KH, Sabbagh A, Fang D, Gupta P, Priebe W, Zielinski R, Burks JK, Long JP, Kong LY, Fuller GN, de Groot JF, Sulman EP, Heimberger AB. Radiation with STAT3 blockade triggers dendritic cell-T cell interactions in the glioma microenvironment and therapeutic efficacy. Clin Cancer Res None(None):None, 2020. e-Pub 2020. PMID: 32605912.
- Kobayashi M, Katayama H, Irajizad E, Vykoukal JV, Fahrmann JF, Kundnani DL, Yu CY, Cai Y, Hsiao FC, Yang WL, Lu Z, Celestino J, Long JP, Do KA, Lu KH, Ladd JJ, Urban N, Bast RC, Hanash SM. Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. Cancers (Basel) 12(2), 2020. e-Pub 2020. PMID: 32092936.
- Amin SB, Anderson KJ, Boudreau CE, Martinez-Ledesma E, Kocakavuk E, Johnson KC, Barthel FP, Varn FS, Kassab C, Ling X, Kim H, Barter M, Lau CC, Ngan CY, Chapman M, Koehler JW, Long JP, Miller AD, Miller CR, Porter BF, Rissi DR, Mazcko C, LeBlanc AK, Dickinson PJ, Packer RA, Taylor AR, Rossmeisl JH, Woolard KD, Heimberger AB, Levine JM, Verhaak RGW. Comparative Molecular Life History of Spontaneous Canine and Human Gliomas. Cancer Cell 37(2):243-257.e7, 2020. PMID: 32049048.
- Lin Z, Long JP. A Flexible Procedure for Mixture Proportion Estimation in Positive-Unlabeled Learning. Data Mining and Statistical Learning 13(None):178-187, 2020. PMID: None.
- Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, Keating MJ, Wierda W, Long JP, Bertilaccio MTS, Gandhi V. AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia. Clin Cancer Res None(None):None, 2020. e-Pub 2020. PMID: 31937611.
- Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen B, Kaseb AO, Kuban JD, Murthy R, Odisio BC, Teyateeti A, Macapinlac HA, Kappadath SC. Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma 7:117-131, 2020. e-Pub 2020. PMID: 32984089.
- Fahrmann JF, Vykoukal J, Fleury A, Tripathi S, Dennison JB, Murage E, Wang P, Yu CY, Capello M, Creighton CJ, Do KA, Long JP, Irajizad E, Peterson C, Katayama H, Disis ML, Arun B, Hanash S. Association between plasma diacetylspermine and tumor spermine synthase with outcome in triple negative breast cancer. J Natl Cancer Inst 112(6):607-616, 2019. e-Pub 2019. PMID: 31503278.
- Stringer K, Long J, Macri L, Marshall J, et al. Identification of RR Lyrae Stars in Multiband, Sparsely Sampled Data from the Dark Energy Survey Using Template Fitting and Random Forest Classification. The Astronomical Journal 158(1):16, 2019. PMID: None.
- Yan Y, Sun N, Wang H, Kobayashi M, Ladd JJ, Long JP, Lo KC, Patel J, Sullivan E, Albert T, Goodman GE, Do KA, Hanash SM. Whole Genome-Derived Tiled Peptide Arrays Detect Prediagnostic Autoantibody Signatures in Non-Small-Cell Lung Cancer. Cancer Res 79(7):1549-1557, 2019. e-Pub 2019. PMID: 30723114.
- Long JP, de Souza RS. Statistical Methods in Astronomy. Wiley StatsRef, 2018. e-Pub 2018. PMID: None.
- Yuan W, He S, Macri LM, Long JP, Huang JZ. The M33 Synoptic Stellar Survey. II. Mira Variables. The Astrophysical Journal 153(4):Article Number 170, 2017. PMID: None.
- Long JP. A note on parameter estimation for misspecified regression models with heteroskedastic errors. Electronic Journal of Statistics 11(1):1464-1490, 2017. PMID: None.
- He S, Yuan W, Huang JZ, Long JP, Macri LM. Period Estimation for Sparsely Sampled Quasi-Periodic Light Curves Applied to Miras. The Astrophysical Journal 152(6):Article Number 164, 2016. PMID: None.
- Salmon B, Papovich C, Long JP, Willner SP, Finkelstein SL, Ferguson HC, Dickinson M, Duncan K, Faber SM, Hathi N, Perez-Gonzalez PG, Pforr J. A Bayesian Approach to Reveal the Non-Universality of the Dust-Attenuation Law at High Redshift. The Astrophysical Journal 827(1):Article Number 20, 2016. PMID: None.
- Long JP, El Karoui N, Rice JA. Kernel Density Estimation with Berkson Error. The Canadian Journal of Statistics 44(2):142-160, 2016. PMID: None.
- Long JP, Chi E, Baraniuk R. Estimating a common period for a set of irregularly sampled functions with applications to periodic variable star data. Annals of Applied Statistics 10(1):165-197, 2016. PMID: None.
- Mondrik N, Long JP, Marshall J. A multiband generalization of the multiharmonic analysis of variance period estimation algorithm and the effect of inter-band observing cadence on period recovery rate. Astrophysical Journal Letters 811(2):Article Number L34, 2015. PMID: None.
- Salmon B, Papovich C, Finkelstein SL, Tilvi V, Finlator K, Behroozi P, Dahlen T, Dave R, Dekel A, Dickinson M, Ferguson HC, Giavalisco M, Long JP, Lu Y, Mobasher B, Reddy N, Somerville RS, Wechsler RH. The Relation Between Star Formation Rate and Stellar Mass for Galaxies at 3.5 < z < 6.5 in CANDELS. The Astrophysical Journal 799(2):Article Number 183, 2015. PMID: None.
- Tilvi V, Papovich C, Finkelstein SL, Long JP, Song M, Dickinson M, Ferguson HC, Koekemoer AM, Giavalisco M, Mobasher B. Rapid Decline of Ly-alpha Emission toward the Reionization Era. The Astrophysical Journal, 2014. PMID: None.
- Long JP, El Karoui N, Rice JA, Richards JW, Bloom JS. Optimizing Automated Classification of variable Stars in new synoptic surveys. Publications of the Astronomical Society of the Pacific 124(913):280-295, 2012. PMID: None.
- Richards JW, Starr DL, Brink H, Miller AA, Bloom JS, Butler NR, James JB, Long JP, Rice JA. Active learning to overcome sample selection bias: Application to photometric variable star classification. The Astrophysical Journal, 2012. PMID: None.
- Morgan AN, Long JP, Richards JW, Broderick T, Butler NR, Bloom JS. Rapid,machine-learned resource allocation: Application to high-redshift GRB follow-up. The Astrophysical Journal, 2012. PMID: None.
- Kinirons P, Rabinowitz D, Gravel M, Long JP, Winawer M, Senechal G, Ottman R, Cossette P. Phenotypic concordance in 70 families with ige-implications for genetic studies of epilepsy. Epilepsy Research 82(1):21-28, 2008. PMID: None.
- Long JP, Yang Y, Shimizu S, Pham T, Do KA. Causal Models and Prediction in Cell Perturbation Experiments. Major Revision at BMC Bioinformatics None(None):None. PMID: None.
Book Chapters
- Long JP, Jack LJ. Inferential Frameworks for Clinical Trials. In: Principles and Practice of Clinical Trials. None. Springer, 2020.
- Long JP, Bloom JS, El Karoui N, Rice JA, and Richards JW. Classification of poorly time sampled light curves of periodic variable stars. In: In Astrostatistics and Data Mining. None. Springer International Publishing, 163-171, 2012.
Grant & Contract Support
| Title: | Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC) |
| Funding Source: | NIH/NCI |
| Role: | Statistician |
| Title: | Development of a Novel Tumor-targeting and Penetrating Nanosystem for Breast Cancer Therapy |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-PI |
| Title: | Developing a novel combination immunotherapy for triple-negative breast cancer |
| Funding Source: | University of Hawaii Cancer Center Subaward-Subcontract |
| Role: | Co-I |
| Title: | Delineating germline, tumor and extrinsic factors driving mucosal melanoma risk and response |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| Title: | Targeting Acquired Resistance in KRAS Driven Cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Deep learning microscope for slide-free and digital histology |
| Funding Source: | NIH/NIDCR subaward via William Marsh Rice University |
| Role: | Co-I |
| Title: | A Phase II Study to evaluate the efficacy and safety of pembrolizumab in combination with mitotane in patients with advanced adrenocortical carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Statistician |
| Title: | IRE-based Rational Combination for Effective PDAC Immunotherapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Title: | RA200128: Enhancing Axl-targeted therapy in inflammatory breast cancer |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| Title: | Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Mechanisms associated with organotropic metastasis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Investigation of the role of epithelial-mesenchymal plasticity in renal cell carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| Title: | Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer |
| Funding Source: | NIH/NCI subaward via Indiana University |
| Role: | Co-I |
| Title: | Chemoimmunotherapy for Aggressive Variant Prostate Cancers (AVPC) |
| Funding Source: | Department of Defense (DOD) |
| Role: | Statistician |
| Title: | Precision Optical Guidance for Oral Biopsy Based on Next-Generation Hallmarks of Cancer |
| Funding Source: | NIH/NIDCR Subaward Rice University |
| Role: | Biostatistician |
| Title: | Cancer Center Support Grant (CCSG) - Biostatistics Resource Group (BRG) |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| Title: | Development of Novel Combinational Therapy with Enzalutamide in AR+ TNBC |
| Funding Source: | Breast Cancer Research Foundation |
| Role: | Co-I |
| Title: | Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Theranostic Heterodimer Eph-Targeting Peptides for Ovarian & Breast Cancer |
| Funding Source: | Emerson Collective Cancer Research Fund |
| Role: | Co-I |
| Title: | Assessing imaging biomarkers for response to combined IRE and anti-PD-1 immunotherapy |
| Funding Source: | QIAC (Quantitative Imaging Analysis Core) |
| Role: | Co-I |
| Title: | Study on the predictability of hormone and chemo resistance in luminal BC patients who have received CDK4/6 inhibitor by Gene Expression Analysis (and analyze TNBC Patients who have FGFR mutations) |
| Funding Source: | Eisai Medical Research subaward via Showa University |
| Role: | Collaborator |
| Title: | Safety and Efficacy of Therapeutic Exosomes in Models of Glioblastoma Multiforme and Leptomeningeal Disease |
| Funding Source: | Codiak Biosciences |
| Role: | Biostatistician |
| Title: | Development of novel therapy by targeting tumor microenvironment in inflammatory breast cancer |
| Funding Source: | Breast Cancer Research Foundation |
| Role: | Co-I |
| Title: | Quantitative Imaging Biomarkers of Immune Response in Melanoma Brain Metastases |
| Funding Source: | MD Anderson – APOLLO Moon Shot Platform |
| Role: | Co-Investigator/Collaborator |
| Title: | 99mTc/Re Biguanide Complexes Targeting Mitochondria for Pancreatic Cancer Theranostics |
| Funding Source: | CABI Pilot Project Program (CP3) |
| Role: | Collaborator |
| Title: | Enhancing EGFR-targeted therapy by blocking immunosuppression in the tumor microenvironment in inflammatory breast cancer |
| Funding Source: | Emerson Collective |
| Role: | Collaborator |
| Title: | SPORE in Brain Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Center for Clinical and Translational Science |
| Funding Source: | NIH/NCATS subaward via UT Health Science Center, Houston |
| Role: | Collaborator |
| Title: | Rigorous and reproducible mutational analysis of the urinary exosomal DNA |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Development of Novel Combinational Therapy with Enzalutamide in AR+ TNBC |
| Funding Source: | Breast Cancer Research Foundation |
| Role: | Co-I |
| Title: | Chemoprevention of Hepatocellular Carcinoma by Disrupting Crosstalk Between c-Myc-expressing Hepatocytes and Hepatic Stellate Cells |
| Funding Source: | Duncan Family Institute for Cancer Prevention and Risk Assessment Seed-funding Research Program |
| Role: | Collaborator |
| Title: | The Transformative Glioblastoma Initiative |
| Funding Source: | Brockman Foundation |
| Role: | Co-I |
| Title: | Translational Applications in an Animal Model of Pancreatic Cystic Neoplasm and Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Mapping Milky Way Halo Structures using Variable Stars in the Dark Energy Survey |
| Funding Source: | Texas A&M |
| Role: | Co-PI |
| Title: | MD Anderson Cancer Center Prostate Cancer SPORE. Core 1: Biostatistics Core |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| Title: | Acute Myeloid Leukemia in the Immunosuppressed |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Biostatistician |
| Title: | A Clinical Validation Center for Early Detection of Pancreatic Cancer |
| Funding Source: | NIH/NCI |
| Role: | Statistician |
| Title: | The CANDELS Lyman-alpha Emission At Reionization (CLEAR) Experiment (STSI Cycle 23 Phase 2) |
| Funding Source: | NASA |
| Role: | Co-I |
| Title: | PTDSS1 as a Novel Target to Improve Anti-tumor Immune Responses with Immune Checkpoint Therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | MD Anderson Cancer Center Prostate Cancer SPORE Core 1: Biostatistics and Bioinformatics |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Establishing a non-invasive immune checkpoint inhibitor associated nephritis signature |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | The Stereotactic Radiologic-Pathologic Imaging Trial: Improving Image-Guided Treatment Planning for Adult Glioma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Electrothermal flow-enhanced biosensor for rapid quantification of acute interstitial nephritis urinary biomarkers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | In Silico Cell Line Perturbation Response Prediction: New Models and Experimental Validation |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | Rapid urine test for detecting cancer immunotherapy toxicity |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Title: | Levels and Trajectories of Exosomal MicroRNAs and Proteins Quantified by an Ultrasensitive Nanoplasmonic Biosensor for Early Detection of Pancreatic Cancer |
| Funding Source: | NCI (subaward via Indiana University) |
| Role: | Co-I |
| Title: | Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC) |
| Funding Source: | NIH/NCI |
| Role: | Statistician |
| Title: | Development of an Immune Checkpoint Inhibitor-associated Nephritis Signature |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | PTDSS1 as a novel target to improve anti-tumor immune responses with immune checkpoint therapy |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Title: | The Stereotactic Radiologic-Pathologic Imaging Trial: Improving Image-Guided Treatment Planning for Adult Glioma |
| Funding Source: | NIH/NCI |
| Role: | Statistician |
| Title: | Developing a novel combination immunotherapy for triple-negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Reduction of Toxicity Using Online Adaptive Radiotherapy for Locally Advanced Cervical Cancer (ROAR C2) FP00018296 |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Development of tumor-specific antibody-drug conjugates for breast cancer |
| Funding Source: | University of Texas at Austin |
| Role: | Co-I |
| Title: | Multi-platform Cellular Perturbation Response Prediction using Deep Learning Causal Models with In Vitro Model Validation |
| Funding Source: | NIH/NHGRI |
| Role: | PD/PI |
| Title: | Rapid urinary test for detecting cancer immunotherapy toxicity |
| Funding Source: | Subaward via William Marsh Rice University |
| Role: | Biostatistician |
| Title: | High Dimensional Causal Discovery for Cellular Perturbation Response Prediction with Application to LINCS L1000 |
| Funding Source: | NIH/NHGRI |
| Role: | PD/PI |
| Title: | Developing a novel combination immunotherapy for triple‐negative breast cancer/ BC220380 |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| Title: | Radiotheranostic Heterodimeric Peptides Targeting EphB4/EphA2 in HGSOC with Adaptive Resistance to Anti-VEGF Therapy |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| Title: | Investigation of functional connection between pulmonary fibrosis and lung cancer |
| Funding Source: | NIH/NHLBI |
| Role: | Collaborator |
| Title: | MD Anderson Cancer Center Prostate Cancer SPORE |
| Funding Source: | NIH/NCI |
| Role: | Core 1 Co-Investigator |
| Title: | LC210324 Blood based biomarkers as a complement to CT screening for lung cancer |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| Title: | Unraveling the functional contribution of extracellular vesicles in pancreatic cancer |
| Funding Source: | NIH-DIVISION OF INTRAMURAL RESEARCH |
| Role: | Collaborator |
| Title: | MD Anderson Cancer Center Prostate Cancer SPORE |
| Funding Source: | NIH/NCI |
| Role: | Core 1 Co-Investigator |
| Title: | Developing a novel combination immunotherapy for triple-negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Exploiting Apoptosis to Induce Immunogenic Cell Death |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Title: | Point-of-care test for patient self-monitoring during cancer immunotherapy |
| Funding Source: | William Marsh Rice University |
| Role: | Biostatistician |
| Title: | Estimation of Aggressive Disease to Guide Surgical Resection In Glioma Patients |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Quantitative Imaging Data Quality Grading System for Robust Training and Deployment of Deep-Learning Algorithms in Cancer |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| Title: | Enhancing Antitumor Immunity with Nanoparticle-mediated Photothermolysis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | The Stereotactic Radiology-Pathology Trial II: Prospective Imaging-Pathologic Correlation in Glioma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Developing a novel combination immunotherapy for triple-negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Blood based biomarkers to complement and expand low-dose CT screening for lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Development of novel tumor microenvironment targeted therapy in inflammatory breast cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Title: | Multimodal Optical Imaging to Improve Real-Time Margin Assessment During Oral Cancer Surgery |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Title: | Blood based biomarkers to complement and expand low-dose CT screening for lung cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Title: | A composite biomarker and radiomic score for risk stratification of indeterminate pulmonary nodules |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | BC210626: Development of novel tumor microenvironment targeted therapy in inflammatory breast cancer |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| Title: | Enhancing Antitumor Immunity with Nanoparticle-mediated Photothermolysis against Hepatocellular Carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | LC200363 Blood-based biomarkers as a complement to CT screening for lung cancer |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| Title: | South Texas Center for Chronic Disease Associated with Health Disparities in Mexican Americans |
| Funding Source: | Subaward-Subcontract from University of Texas Rio Grange Valley School of Medicine |
| Role: | Biostatistician |
| Title: | Quantitative Imaging Data Quality Grading System for Robust Training and Deployment of Deep-Learning Algorithms in Cancer |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| Title: | Potentiation of Anti-Angiogenic Therapy by Inhibitors of Energy Metabolism |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Developing a novel combination immunotherapy for triple-negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Enhancing Antitumor Immunity with Nanoparticle-mediated Photothermolysis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Modulation of Microglia and T Cell Interactions in Malignant Glioma |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| Title: | Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Reversing glioblastoma immunosuppression by aptamer targeting of therapeutic siRNAs |
| Funding Source: | NIH/NINDS |
| Role: | Biostatistician |
| Title: | AI-Enabled WHO Grade Estimation to Guide Accurate Biopsy in Gliomas |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| Title: | Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Extracellular Vesicle based Liquid Biopsy for Monitoring Therapy Response in Pancreatic Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Defining lineage plasticity in androgen-indifferent prostate cancer |
| Funding Source: | The Mike Slive Foundation |
| Role: | Statistics Expert |
| Title: | Manipulating the Microenvironment in a Murine Glioma Model |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Stereotactic Ablative Radiotherapy for Refractory Lethal Structural Arrhythmias (SABR-Heart) |
| Funding Source: | Patient Centered Outcomes Res Inst PCORI |
| Role: | Biostatistician |
| Title: | BC200327: Development of a novel JNK-targeted therapy to enhance immunotherapy efficacy in triple-negative breast cancer |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| Title: | JNKs Regulation of Metastatic Tumor Microenvironment in Triple-Negative Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Myeloid-mediated mechanisms underlying de novo and acquired resistance against immune checkpoint blockade therapies for triple-negative breast cancer |
| Funding Source: | John S Dunn Research Foundation |
| Role: | Co-I |
| Title: | Modulation Of The Glioblastoma Immune Landscape With STING |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| Title: | Potentiation of Anti-angiogenic Therapy by Inhibitors of Energy Metabolism |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | A Machine Learning Solution for Estimating the Proliferative Marker Ki-67 in Gliomas to Guide Accurate Biopsy, Surgical Planning and Radiation Planning |
| Funding Source: | InformAl |
| Role: | Co-I |
| Title: | Quantitative imaging for risk stratification and early detection of hepatocellular carcinoma |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Biostatistician |
| Title: | 99mTc/Re Biguanide Complexes as Imaging Probes and Metabolic Modulators for PDAC Theranostics |
| Funding Source: | MD Anderson Institutional Research Grant |
| Role: | Collaborator |
| Title: | Pharmacological Reprogramming of Cancer-Associated Fibroblasts in PDAC |
| Funding Source: | Pancreatic Cancer Action |
| Role: | Co-I |
| Title: | Deconstructing AMPK Activity in Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Title: | Modulation of Microglia and T Cell Interactions in Malignant Glioma |
| Funding Source: | NIH/NCI |
| Role: | Biostatician |
| Title: | Mechanisms associated with organotropic metastasis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Imaging Biomarkers of Response to Irreversible Electroporation and Anti-PD-1 |
| Funding Source: | Pancreatic Cancer Action |
| Role: | Co-I |
| Title: | Re-Programming Cancer Associated Fibroblasts in Pancreatic Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Application of spatially precise imaging-pathology correlations for improved image guidance of stereotactic biopsy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Chemoprevention of Hepatocellular Carcinoma by Deactivation of Hepatic Stellate Cells |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Title: | Evolution of the immune microenvironment as determinants of breast ductal carcinoma in situ progression |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Title: | Multimodal Optical Imaging to Improve Real-Time Margin Assessment During Oral Cancer Surgery |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Development of Novel Therapy by Targeting Tumor Microenvironment in Inflammatory Breast Cancer |
| Funding Source: | Breast Cancer Research Foundation |
| Role: | Co-I |
| Title: | Evolution of the immune microenvironment as determinants of breast ductal carcinoma in situ progression |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| Title: | Anti-PD-1 exerts therapeutic effects against glioblastoma through innate immunity in the CNS |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| Title: | Integrative Proteomic-based Biomarker Discovery and Validation of Common Salivary Gland Carcinomas |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| Title: | Center of Excellence in Rare Salivary Gland Cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Imaging and Pathology Quantification of Glioma Heterogeneity |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Co-PI |
| Title: | Multi-Modal Imaging System with Automated Image Analysis for Longitudinal Surveillance and Accurate, Timely Risk Assessment of Oral Precancers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Assessing Imaging Biomarkers for Response to Combined IRE and Anti-PD-1 Immunotherapy |
| Funding Source: | MDACC Sister Institution Network Fund |
| Role: | Collaborator |
| Title: | The Stereotactic Radiologic-Pathologic Imaging Trial: Improving Image-Guided Treatment Planning for Adult Glioma |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Co-I |
| Title: | Levels and Trajectories of Exosomal MicroRNAs and Proteins Quantified by an Ultrasensitive Nanoplasmonic Biosensor for Early Detection of Pancreatic Cancer |
| Funding Source: | INDIANA UNIVERSITY |
| Role: | PD/PI |
| Title: | Human Mesenchymal Stem Cells Loaded with a Tumor Selective Oncolytic Adenovirus Administered via Intra-Arterial Injection in Patients with Recurrent High Grade Gliomas |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Co-I |
| Title: | Enabling Differential Expression Analysis with In Silico Perturbation Models: New Methodology and Rigorous Testing |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | PD/PI |
| Title: | In Silico Cell Line Perturbation Response Prediction: New Models and Experimental Validation |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | PD/PI |
| Title: | Leveraging Prostate Cancer’s Unique Lipid Metabolism to Induce Therapeutic Ferroptosis |
| Funding Source: | US Department of Defense |
| Role: | Statistician |
| Title: | RP250154: Improving Detection of Hepatocellular Carcinoma in Non-Cirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASLD) Patients |
| Funding Source: | CANCER PREVENTION RESEARCH INST OF TX |
| Role: | Biostatistician |
| Title: | Imaging and Genomic biomarkers for detection of MASLD-related HCC |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Biostatistician |
| Title: | A Novel Tumor-Targeting and Penetrating Nanoparticle for Simultaneous Delivery of Multiple Therapeutics for Advanced Ovarian Cancer |
| Funding Source: | EnduRX Pharmaceuticals, Inc |
| Role: | Co-I |
| Title: | Histone lactylation(s) orchestrate epigenetic and transcriptional networks driving CD8 T cell metabolism and function |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Co-I |
| Title: | SPORE in Brain Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Director |
| Title: | The Role of CDKN2A inactivation as a mediator of immunosuppression in pancreatic cancer |
| Funding Source: | CONQUER CANCER FOUNDATION |
| Role: | Co-I |
| Title: | Center for Clinical and Translational Science - UM1 |
| Funding Source: | University of Tx Health Science Center - Houston |
| Role: | BERD co-investigator |
| Title: | Exosomes and MicroRNA in Glioma Therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | BC190193P1 Development of a Novel Tumor-targeting and Penetrating Nanosystem for Breast Cancer Therapy |
| Funding Source: | US Department of Defense |
| Role: | PD/PI |
| Title: | Enhancing Axl-targeted therapy in inflammatory breast cancer |
| Funding Source: | University of Hawaii Cancer Center Subaward-Subcontract |
| Role: | Co-I |
| Title: | Developing a novel combination immunotherapy for triple-negative breast cancer |
| Funding Source: | University of Hawaii Cancer Center |
| Role: | Co-I |
| Title: | Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer |
| Funding Source: | NIH/NCI, Subaward VIA University of Hawaii Cancer Center |
| Role: | Co-I |
Patient Reviews
CV information above last modified November 11, 2024